Page 109 - CIBERBBN-2015-eng

aging techniques, combining invasive and non-inva- sive procedures.
This unit also enables nanomedicine-based ther- apies to be tested on conventional cell lines and primary cultures (loss and gain of function exper-
iments and gene expression analysis, as well as studying control of expression at various levels: transcriptional [gene transfection, inducible sys- tems], posttranscriptional [RNAi] and at the protein level [antagonists and antibody neutralization]).
Most relevant scientific articles
Research groups
ANDRADE F., NEVES J.D., GENER P., SCHWARTZ S., FERREIRA D., OLIVA M. ET AL. Biological assessment of self-assem- bled polymeric micelles for pulmonary administration of insulin. Nanomedicine: Nanotechnology, Biology, and Medicine. 2015;11(7):1621-1631.
GENER P., GOUVEIA L.P., SABAT G.R., DE SOUSA RAFAEL D.F., FORT N.B., ARRANJA A. ET AL. Fluorescent CSC models evidence that targeted nanomedicines improve treat- ment sensitivity of breast and colon cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine. 2015;11(8):1883-1892.
BAZZOCCO S., DOPESO H., CARTON-GARCíA F., MACAYA I., ANDRETTA E., CHIONH F. ET AL. Highly expressed genes
Highlights
The group on Drug Delivery and Targeting seeks two main goals; on the one hand, the identification of new disease biomarkers and therapeutic targets, with special focus on cancer, and on the other hand, the development of new drug delivery and targeting approaches for clinical applications. Among our pro- jects are two new EuroNanoMed II projects focused in nanomedicine applications involving SME’s in which animal models are being used for preclinical validation of new therapies directed against tumor cells (DiamESTar, Targets4Cancer), and four addi- tional projects, one of them from Marató TV3, Pentri: for active targeting against cancer stem cells), a RE- TOS project recently approved together with SMEs and focused into scale-up and preclinical validation of drug delivery systems, and an H2020 European project recently approved (Nocanther). Additional
in rapidly proliferating tumor cells as new targets for colorectal cancer treatment. Clinical Cancer Research. 2015;21(16):3695-3704.
CARTON-GARCíA F., OVEREEM A.W., NIETO R., BAZZOCCO S., DOPESO H., MACAYA I. ET AL. Myo5b knockout mice as a model of microvillus inclusion disease. Scientific Reports. 2015;5.
MORAL-VICO J., BARALLAT J., ABAD L., OLIVE-MONLLAU R., MUNOZ-PASCUAL F.X., GALAN ORTEGA A. ET AL. Dual chron- oamperometric detection of enzymatic biomarkers using magnetic beads and a low-cost flow cell. Biosensors and Bioelectronics. 2015;69:328-336.
National grants were also obtained. Several in vitro and in vivo cancer models have been generated by the group for preclinical testing of nanomedicines, including the generation of specific cancer stem cell models. Two patents from the group are in Na- tional Fases. Dr Schwartz Jr is also member of the Nanomedicine Spanish Platform (NanomedSpain), the “European Platform for Nanomedicine” and the “European Fundation for Clinical Nanomedicine” (CLINAM). Dr Schwartz has also been appointed as Scientific Advisor by the Southern Denmark Uni- versity of the excellence center NANOCAN for Na- nomedicine andacts as an external evaluator of the Swedish Research Council and associate editor of Nanomedicine NMB an European J Nanomedicine. Further, Dr Schwartz’s group published papers in top science journals in 2015.
Institution: Fundación Hospital Universitario Vall d´Hebron - Institut de Recerca (VHIR) Contact: Hospital Vall d’Hebron · Passeig Vall d’Hebron, 119-129 08035 Barcelona Tel.: 93 489 4053 · E.mail: [email protected] · Website: http://www.cibbim.eu/
CIBER-BBN I Annual report 2015 I 109